Income Statement Balance Sheet Cash Flow Segments

Neurocrine Biosciences Business Segments

Business, geographic, and product segment breakdowns

Neurocrine Biosciences generates $3.1B in annual revenue across 1 key segments: Business Segments ($56.7M). The company-wide operating margin is 25.43%. Based on the Q1 2026 filing.

Business Segments (TTM)$56.7M

Latest FilingQ1 2026

Report Date2026-05-05

Market Cap$16.4B

P/E Ratio24.47

ROE22.5%

Products & Services

Metric	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Total revenues	$6.5M	$8.9M	$5.5M	$5M	$7.2M	$3.5M

Business Segments

Metric	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Total revenues	$627.7M	$572.6M	$687.5M	$794.9M	$805.5M	$814.5M
Selling, general, and administrative	$287.8M	$276.5M	$286.3M	$291.6M	$301.8M	$318.5M
R&D	$185.6M	$263.2M	$244.3M	$250M	$258.2M	$296.2M
Net Income	$103.1M	$7.9M	$107.5M	$209.5M	$153.7M	$197.9M
Provision for income taxes	$59.5M	$6.8M	$52M	$82.3M	$85.7M	$48.9M
Investment income and other, net	$22.5M	$21.7M	$20.6M	$22.2M	$25.8M	$28.1M
Unrealized gain (loss) on equity investments	-$1.9M	-$30.6M	-$6.7M	$30.6M	—	$25.3M
Acquired in-process research and development	$3M	$100K	$0	$300K	$17M	$21.2M
Cost of revenues	$9.3M	$9.2M	$11.3M	$14M	$17.6M	$13.8M